Welcome to our dedicated page for Centogene N.V. Common Shares news (Ticker: CNTG), a resource for investors and traders seeking the latest updates and insights on Centogene N.V. Common Shares stock.
Centogene N.V. (symbol: CNTG) is a leading global company in the field of genetic diagnostic testing for rare hereditary diseases. With an expansive test portfolio covering over 2,800 genes, as well as biochemical and biomarker tests, the company offers unparalleled expertise in whole exome sequencing and whole genome sequencing. Centogene's mission is to provide data-driven, life-changing answers to patients, physicians, and pharmaceutical companies by diagnosing the root causes of symptoms early on.
Centogene leverages its unique CentoMD® mutation database, integrating genetic and clinical information to deliver the highest quality genetic testing and biomarker development. This extensive database allows the company to maintain the largest systematic documentation of genetic results worldwide.
Beyond individual diagnostic services, Centogene is a pivotal partner for pharmaceutical companies, offering essential services such as early patient recruitment, epidemiological insights, biomarker discovery, and patient monitoring. The company operates in two main segments: pharmaceutical and diagnostics, serving regions including Europe, the Middle East, North America, and Latin America.
Recent achievements include the launch of innovative genomic and multiomic products, a significant joint venture in Saudi Arabia, and expanded collaborations with long-standing and new pharma partners. Despite the challenges posed by current financial markets, Centogene remains committed to growth and profitability, exploring strategic alternatives to unlock value for its stakeholders.
With ISO, CAP, and CLIA certified multiomic reference laboratories in Germany, Centogene's research and development efforts have led to over 285 peer-reviewed publications. The company's pioneering work in rare and neurodegenerative diseases has fostered collaborations with over 50 pharmaceutical partners, accelerating drug discovery and development.
To discover more about Centogene's products, pipeline, and patient-driven purpose, visit their website and follow them on LinkedIn.
Centogene N.V. (Nasdaq: CNTG) has appointed Dr. Patrice P. Denèfle as the new Chief Scientific Officer, effective August 16, 2021. Dr. Denèfle brings over 35 years of experience in the pharmaceutical and biotechnology sectors, having held prominent roles at various companies. He succeeds Phil Lambert, who is leaving the company. Under Dr. Denèfle’s leadership, Centogene aims to enhance its scientific capabilities and drive growth, targeting the development of therapies for 100 rare diseases within a decade.
Centogene N.V. (Nasdaq: CNTG) reported positive results from its Annual General Meeting held on June 25, 2021, where shareholders approved all proposals, including the appointment of Rene Just as Chief Financial Officer. Peer Schatz, Chairman of the Supervisory Board, thanked shareholders for their support in advancing the company's mission to address the challenges of rare diseases. Centogene's proprietary platform leverages comprehensive data from over 600,000 patients, aiming to enhance understanding and treatment of rare hereditary diseases and accelerating orphan drug development.
Centogene (Nasdaq: CNTG) hosted a Virtual Investor Event to outline strategic priorities aimed at enhancing data-driven insights into rare diseases. The company emphasized its goal to reduce the burden of rare diseases, targeting the development of 100 cures within 10 years. Key initiatives include expanding a rare disease-centric Bio/Databank to 1 million patients and developing 10 full disease models. Centogene aims to leverage its expertise and global network to accelerate orphan drug development.
Centogene N.V. (CNTG) reported Q1 2021 revenues of €65.0 million, a remarkable increase of over 400% from €12.1 million in Q1 2020, largely driven by COVID-19 testing. The company achieved positive adjusted EBITDA while investing heavily in its rare disease core business, adding over 25,000 patients to its Bio/Databank. Noteworthy new partnerships in Pharma and management team expansions were announced, supporting ongoing recovery in its diagnostics segment. However, uncertainties remain regarding COVID-19 testing revenues for 2021, which are anticipated to match 2020 levels.
Centogene N.V. (Nasdaq: CNTG) announced it will release financial results for Q1 2021 on June 16, 2021. A Virtual Investor Event is scheduled for June 22, 2021, between 9:00 a.m. - 11:00 a.m. EDT. The company focuses on generating insights for diagnosing rare diseases, utilizing a vast database from approximately 600,000 patients across over 120 countries. Centogene collaborates with more than 30 pharmaceutical partners to enhance orphan drug development.
Centogene N.V. will hold a Virtual Investor Event on June 22, 2021, showcasing its leadership team's vision and strategy for the future. The company, a leader in rare genetic disease diagnostics, aims to leverage its extensive Bio/Databank to enhance orphan drug development. The event will discuss Centogene's strategy to create value for both patients and investors. The company has collaborated with over 30 pharmaceutical partners and possesses a rare disease platform with over 3.9 billion data points from approximately 600,000 patients.
Centogene N.V. (Nasdaq: CNTG) has initiated the EFRONT Study to investigate genetic mutations in frontotemporal dementia (FTD) patients, supported by Alector, Inc. (Nasdaq: ALEC). The study aims to enroll over 3,000 participants across multiple European countries, utilizing Centogene's Bio/Databank for genetic testing. FTD, affecting approximately 110,000 patients in the EU and 50,000 in the U.S., currently has no approved treatments. The collaboration aims to deepen understanding of FTD's genetic factors, ultimately facilitating new treatment developments.
CENTOGENE N.V. (Nasdaq: CNTG) has launched NEW CentoXome, a next-generation sequencing solution designed for diagnosing rare diseases. This enhanced Whole Exome Sequencing (WES) solution increases diagnostic yield by up to 20% compared to conventional WES. Leveraging CENTOGENE’s extensive Bio/Databank, which includes data from approximately 600,000 patients, the CentoXome provides improved clinical reporting and enhanced coverage across crucial genes. The new service is complemented by lifelong diagnostic support and a proactive variant reclassification program.
Centogene N.V. (Nasdaq: CNTG) has nominated Rene Just as the new Chief Financial Officer (CFO), effective June 1, 2021. This change comes as current CFO Richard Stoffelen steps down on June 30, 2021. Just brings over 20 years of finance experience, previously serving as Group CFO at Riemser Pharma Holding. Under Stoffelen's leadership, Centogene grew significantly, achieving record revenues in 2020. The company plans to outline its vision and strategy at an upcoming investor event on June 22.
Centogene N.V. (Nasdaq: CNTG) announced the appointment of Dr. Michael Motz as Chief Commercial Officer, Pharmaceuticals, effective June 1, 2021. Dr. Motz, a seasoned executive with over 25 years of experience in biotech and pharmaceuticals, will leverage his expertise in drug discovery and development for rare diseases. His role will be crucial in utilizing Centogene’s Bio/Databank to advance innovations in genetic hereditary diseases.
The company has a robust platform with over 3.9 billion data points from approximately 600,000 patients, positioning it strongly in the rare disease market.
FAQ
What is the current stock price of Centogene N.V. Common Shares (CNTG)?
What is the market cap of Centogene N.V. Common Shares (CNTG)?
What does Centogene N.V. specialize in?
What is CentoMD®?
Which segments does Centogene operate in?
What regions does Centogene serve?
Who are Centogene’s main partners?
What are some recent achievements of Centogene?
How does Centogene contribute to drug discovery?
What research certifications does Centogene hold?
How extensive is Centogene's physician network?
Where can I learn more about Centogene?
